8-K: Sight Sciences Reports Q4 Growth, Initiates 2026 Guidance

Sight Sciences reported a return to growth in Q4 2025, driven by Interventional Glaucoma, and initiated positive revenue guidance for 2026.

Summary

• Total revenue for Q4 2025 was $20.4 million, an increase of 7% compared to the same period in the prior year.
• Full year 2025 total revenue was $77.4 million, a decrease of 3% compared to full year 2024.
• Interventional Glaucoma revenue in Q4 2025 increased by 5% to $19.7 million, while Interventional Dry Eye revenue grew to $0.7 million from $0.3 million in the prior year's quarter.
• Full year 2025 Interventional Glaucoma revenue was $75.7 million, flat compared to full year 2024, and Interventional Dry Eye revenue was $1.6 million, down from $4.0 million in full year 2024.
• Total gross margin was 87% in Q4 2025 and 86% for full year 2025, an increase from 85% in full year 2024.
• Operating expenses for full year 2025 were reduced by 13% to $103.8 million compared to full year 2024.
• Net loss for Q4 2025 improved to $4.2 million, or $0.08 per share, from $11.8 million, or $0.23 per share, in Q4 2024.
• Full year 2025 net loss improved to $38.4 million, or $0.74 per share, from $51.5 million, or $1.03 per share, in full year 2024.
• Cash and cash equivalents totaled $92.0 million as of December 31, 2025, with cash usage of $0.4 million in Q4 2025, but $28.4 million for the full year 2025.
• The company initiated full year 2026 revenue guidance of $82 million to $88 million, representing 6% to 14% growth over 2025.
• 2026 guidance includes Interventional Glaucoma revenue of $77 million to $81 million and Interventional Dry Eye revenue of $5 million to $7 million.
• Adjusted operating expenses for full year 2026 are expected to range from $93 million to $96 million, an increase of 6% to 9% compared to 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, reflecting a return to growth in Q4, significant expense management, and an optimistic outlook for 2026, particularly with the expected ramp-up in Interventional Dry Eye revenue.

Positives

• Returned to growth in Interventional Glaucoma in Q4 2025, with revenue increasing 5% year-over-year to $19.7 million.
• Demonstrated encouraging commercial traction in Interventional Dry Eye following significant reimbursement milestones, with Q4 2025 revenue increasing from $0.3 million to $0.7 million year-over-year.
• Achieved a full year 2025 operating expense reduction of 13% compared to full year 2024, totaling $103.8 million.
• Reduced cash usage to $0.4 million in the fourth quarter of 2025, reflecting continued operating discipline.
• Maintained a strong cash position with $92.0 million in cash and cash equivalents as of December 31, 2025.
• Improved full year 2025 net loss to $38.4 million, or $0.74 per share, from $51.5 million, or $1.03 per share, in 2024.
• Initiated full year 2026 revenue guidance of $82 million to $88 million, representing 6% to 14% growth compared to 2025.
• Interventional Dry Eye gross margin significantly increased to 68.4% in Q4 2025 from 51.0% in Q4 2024, and to 59.3% for full year 2025 from 46.2% in 2024, primarily due to higher average selling prices.

Negatives

• Full year 2025 total revenue decreased by 3% to $77.4 million compared to full year 2024.
• Full year 2025 Interventional Dry Eye revenue significantly decreased to $1.6 million compared to $4.0 million in full year 2024.
• Cash used in full year 2025 totaled $28.4 million, an increase from $17.8 million in full year 2024.
• Interventional Glaucoma gross margin for full year 2025 slightly decreased to 86.8% from 87.6% in full year 2024, primarily due to higher tariff costs.

Risks

• Changes to reimbursement coverage or payment decisions or reimbursement rates for products.
• Pricing pressure or changes in market share resulting from the evolving competitive landscape.
• The impact of tariffs on products and the medical device industry generally.
• Disruptions to or increased costs associated with the supply chain, including as a result of having a limited number of suppliers.

Future Outlook

The company expects full year 2026 revenue to range from $82 million to $88 million, representing 6% to 14% growth over 2025. This includes Interventional Glaucoma revenue of $77 million to $81 million (2% to 7% growth) and Interventional Dry Eye revenue of $5 million to $7 million (significant growth from $1.6 million in 2025). Adjusted operating expenses are projected to increase by 6% to 9% to $93 million to $96 million, driven by targeted investments in market access and commercial resources for dry eye and pseudophakic standalone glaucoma opportunities. The company remains focused on building a leading interventional eye care company and leveraging synergistic growth with a pathway toward cashflow breakeven.

Management Comments

• "We closed the year with a solid fourth quarter, where we returned to growth in Interventional Glaucoma, demonstrated encouraging commercial traction following significant reimbursement milestones in Interventional Dry Eye, and continued our disciplined expense and cash management."
• "These achievements underscore the strength of our interventional technologies and commercial infrastructure in the large and growing glaucoma and dry eye markets."
• "In 2026, we remain focused on building a leading interventional eye care company and leveraging the complementary nature of our two interventional businesses to drive synergistic growth with a pathway toward cashflow breakeven."

Industry Context

StockSavvy.ai notes that Sight Sciences operates in the large and underserved markets of glaucoma and dry eye disease, which collectively represent multi-billion dollar opportunities. The company's focus on interventional technologies, such as the OMNI Surgical System for glaucoma and the TearCare System for dry eye, positions it to address limitations of conventional treatments like daily eye drops, which often suffer from poor patient compliance. The recent reimbursement milestones for Interventional Dry Eye are critical for scaling commercial efforts in a market historically dominated by pharmaceutical solutions.

Comparison to Industry Standards

• The OMNI Surgical System offers leading clinical outcomes for Primary Open-Angle Glaucoma (POAG), with over 370,000 procedures performed as of December 31, 2025.
• OMNI is the only MIGS device with an FDA indication that allows for use in combination cataract or standalone procedures, access to 360 degrees of the diseased conventional outflow pathway, comprehensive treatment of all three areas of resistance in the diseased conventional outflow pathway, and use in adult patients with POAG across the spectrum of disease severity.
• The SAHARA Randomized Controlled Trial demonstrated TearCare's clinical superiority in its primary signs endpoint (TBUT) compared to Restasis (an Allergan, Inc. product), and showed significant improvements in all signs and symptoms of dry eye disease.
• A published budget impact analysis indicates economic savings for payors with the TearCare System compared to a commonly used prescription dry eye medication.
• TearCare treatment provided two years of relief for 66% of patients in the SAHARA study, suggesting a durable treatment effect compared to daily drop regimens.

Stakeholder Impact

• Shareholders: Potential for increased value due to projected revenue growth, improved financial performance (reduced net loss), and disciplined expense management.
• Patients: Continued access to innovative interventional technologies for glaucoma and dry eye, with demonstrated clinical efficacy and durability.
• Employees: Targeted investments in business segments and commercial resources may lead to job growth and stability.
• Customers (Eyecare Providers): Enhanced product offerings and market access support for OMNI and TearCare systems, potentially leading to broader adoption.

Next Steps

• Focus on building a leading interventional eye care company in 2026.
• Leverage the complementary nature of the two interventional businesses to drive synergistic growth.
• Work towards a pathway toward cashflow breakeven.
• Targeted investments in both business segments, including expanded market access efforts and additional commercial resources to scale the reimbursed dry eye market and the pseudophakic standalone glaucoma opportunity in 2026.
• Host a conference call on March 4, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Key Dates

Recommendation

While the Q4 results show a positive turn and the 2026 guidance is encouraging, particularly for the Interventional Dry Eye segment, the full year 2025 revenue decline and increased cash usage for the full year suggest that the company is still in a transitional phase. The projected growth for 2026 is solid, but the company is not yet cashflow breakeven. The stock may see some positive movement on the Q4 performance and guidance, but a "hold" recommendation allows investors to observe the execution of the 2026 strategy and the path to profitability before committing to a stronger position. The risks related to reimbursement, competition, and tariffs also warrant caution.

Keywords

eyecare technology, glaucoma, dry eye, OMNI Surgical System, TearCare System, MIGS, MGD, interventional ophthalmology, medical devices, financial results, revenue guidance